Laboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, University of Western Australia, Centre for Medical Research, QEII Medical Centre, 6 Verdun St, Nedlands, WA, 6009, Australia.
School of Medicine and Pharmacology, the University of Western Australia, Nedlands, WA, 6009, Australia.
BMC Biotechnol. 2018 Mar 16;18(1):16. doi: 10.1186/s12896-018-0421-6.
microRNAs (miRNAs) are short non-coding RNAs that fine-tune gene expression. The aberrant expression of miRNAs is associated with many diseases and they have both therapeutic and biomarker potential. However, our understanding of their usefulness is dependent on the tools we have to study them. Previous studies have identified the need to optimise and standardise RNA extraction methods in order to avoid biased results. Herein, we extracted RNA from murine lung, liver and brain tissues using five commercially available total RNA extraction methods. These included either: phenol: chloroform extraction followed by alcohol precipitation (TRIzol), phenol:chloroform followed by solid-phase extraction (column-based; miRVana and miRNeasy) and solid-phase separation with/without affinity resin (Norgen total and Isolate II). We then evaluated each extraction method for the quality and quantity of RNA recovered, and the expression of miRNAs and target genes.
We identified differences between each of the RNA extraction methods in the quantity and quality of RNA samples, and in the analysis of miRNA and target gene expression. For the purposes of consistency in quantity, quality and high recovery of miRNAs from tissues, we identified that Phenol:chloroform phase separation combined with silica column-based solid extraction method was preferable (miRVana microRNA isolation). We also identified a method that is not appropriate for miRNA analysis from tissue samples (Bioline Isolate II). For target gene expression any of the kits could be used to analyse mRNA, but if interested in analysing mRNA and miRNA from the same RNA samples some methods should be avoided.
Different methods used to isolate miRNAs will yield different results and therefore a robust RNA isolation method is required for reproducibility. Researchers should optimise these methods for their specific application and keep in mind that "total RNA" extraction methods do not isolate all types of RNA equally.
microRNAs (miRNAs) 是一种短的非编码 RNA,可以精细调控基因表达。miRNAs 的异常表达与许多疾病有关,它们具有治疗和生物标志物的潜力。然而,我们对它们的用途的理解取决于我们用来研究它们的工具。先前的研究已经确定需要优化和标准化 RNA 提取方法,以避免产生有偏差的结果。在此,我们使用五种市售的总 RNA 提取方法从鼠肺、肝和脑组织中提取 RNA。这些方法包括:苯酚:氯仿提取后用乙醇沉淀(TRIzol)、苯酚:氯仿提取后固相萃取(基于柱的;miRVana 和 miRNeasy)和固相分离有/无亲和树脂(Norgen 总 RNA 提取试剂盒和 Isolate II)。然后,我们评估了每种提取方法回收的 RNA 的质量和数量,以及 miRNA 和靶基因的表达情况。
我们发现,在 RNA 样品的数量、质量和 miRNA 的分析中,每种 RNA 提取方法之间存在差异。为了保证从组织中提取 miRNA 的一致性,我们确定了苯酚:氯仿相分离与硅胶柱固相萃取方法相结合(miRVana 微 RNA 分离试剂盒)是首选方法。我们还发现一种不适合从组织样品中分析 miRNA 的方法(Bioline Isolate II)。对于靶基因的表达,任何试剂盒都可以用于分析 mRNA,但如果有兴趣从同一份 RNA 样品中分析 mRNA 和 miRNA,则应避免使用某些方法。
不同的方法用于分离 miRNA 会产生不同的结果,因此需要一种稳健的 RNA 分离方法来保证结果的可重复性。研究人员应根据其特定的应用优化这些方法,并牢记“总 RNA”提取方法并不能平等地分离所有类型的 RNA。